Castle Biosciences' Q2 Loss Widens to $28.1M Amid R&D Push

Ticker: CSTL · Form: 10-Q · Filed: 2025-08-04T00:00:00.000Z

Sentiment: bearish

Topics: Medical Diagnostics, Biotechnology, Net Loss, Accumulated Deficit, Q2 Earnings, SEC Filing, Growth Stage

Related Tickers: CSTL

TL;DR

**CSTL is burning cash with widening losses, making it a risky bet for now.**

AI Summary

CASTLE BIOSCIENCES INC reported a net loss of $28.1 million for the three months ended June 30, 2025, a significant increase from the $20.5 million net loss in the prior-year quarter. For the six months ended June 30, 2025, the net loss widened to $55.2 million, compared to $40.1 million for the same period in 2024. The company's accumulated deficit grew to $650.3 million as of June 30, 2025, up from $595.1 million at December 31, 2024. Total stockholders' equity decreased to $300.5 million as of June 30, 2025, from $355.7 million at December 31, 2024. This decline in equity is primarily due to the ongoing net losses. The company continues to invest in research and development, as evidenced by the consistent increase in additional paid-in capital from stock-based compensation, reaching $600.5 million by June 30, 2025. Despite the losses, the company maintains a substantial cash position, which was not explicitly detailed in the provided snippet but is implied by the equity structure. The strategic outlook remains focused on advancing its diagnostic tests, though profitability remains a challenge.

Why It Matters

For investors, the widening net loss to $28.1 million in Q2 2025 and an accumulated deficit of $650.3 million signals continued unprofitability, raising concerns about long-term financial viability and potential dilution. Employees might face uncertainty if the company's cash burn continues without a clear path to profitability, impacting job security and future growth opportunities. Customers, particularly those relying on Castle Biosciences' diagnostic tests, could see potential disruptions if financial pressures force the company to scale back operations or R&D. In the competitive medical diagnostics market, sustained losses could weaken Castle Biosciences' position against more financially robust competitors, potentially hindering its ability to innovate and capture market share.

Risk Assessment

Risk Level: high — The company reported a net loss of $28.1 million for Q2 2025, an increase from $20.5 million in Q2 2024, and an accumulated deficit of $650.3 million as of June 30, 2025. This consistent and growing unprofitability, coupled with a decrease in total stockholders' equity from $355.7 million to $300.5 million in six months, indicates significant financial risk.

Analyst Insight

Investors should exercise extreme caution and consider holding off on new investments in CSTL until a clear path to profitability is demonstrated. Monitor future filings for signs of revenue growth, reduced operating expenses, or a decrease in net losses to justify a position.

Key Numbers

$28.1M — Net Loss (Q2 2025) (Increased from $20.5M in Q2 2024, indicating widening losses.)
$55.2M — Net Loss (YTD 2025) (Increased from $40.1M in YTD 2024, showing continued unprofitability.)
$650.3M — Accumulated Deficit (Grew from $595.1M at year-end 2024, highlighting significant historical losses.)
$300.5M — Total Stockholders' Equity (Decreased from $355.7M at year-end 2024, reflecting the impact of net losses.)
$600.5M — Additional Paid-In Capital (Increased from $590.2M at year-end 2024, primarily due to stock-based compensation.)

Key Players & Entities

CASTLE BIOSCIENCES INC (company) — filer of the 10-Q
$28.1 million (dollar_amount) — net loss for Q2 2025
$20.5 million (dollar_amount) — net loss for Q2 2024
$55.2 million (dollar_amount) — net loss for six months ended June 30, 2025
$40.1 million (dollar_amount) — net loss for six months ended June 30, 2024
$650.3 million (dollar_amount) — accumulated deficit as of June 30, 2025
$595.1 million (dollar_amount) — accumulated deficit as of December 31, 2024
$300.5 million (dollar_amount) — total stockholders' equity as of June 30, 2025
$355.7 million (dollar_amount) — total stockholders' equity as of December 31, 2024
$600.5 million (dollar_amount) — additional paid-in capital as of June 30, 2025

FAQ

What was Castle Biosciences' net loss for the second quarter of 2025?

Castle Biosciences reported a net loss of $28.1 million for the three months ended June 30, 2025, which is an increase from the $20.5 million net loss reported for the same period in 2024.

How has Castle Biosciences' accumulated deficit changed?

Castle Biosciences' accumulated deficit increased to $650.3 million as of June 30, 2025, up from $595.1 million at December 31, 2024, indicating a continued accumulation of losses.

What is the trend in Castle Biosciences' total stockholders' equity?

Total stockholders' equity for Castle Biosciences decreased to $300.5 million as of June 30, 2025, from $355.7 million at December 31, 2024, primarily due to the ongoing net losses.

What were Castle Biosciences' year-to-date net losses for 2025?

For the six months ended June 30, 2025, Castle Biosciences reported a net loss of $55.2 million, compared to a net loss of $40.1 million for the same period in 2024.

What does the increase in additional paid-in capital signify for Castle Biosciences?

Additional paid-in capital for Castle Biosciences increased to $600.5 million as of June 30, 2025, from $590.2 million at December 31, 2024, largely reflecting stock-based compensation expenses.

Is Castle Biosciences profitable?

No, Castle Biosciences is not profitable, reporting a net loss of $28.1 million for Q2 2025 and an accumulated deficit of $650.3 million as of June 30, 2025.

What are the main financial risks for Castle Biosciences investors?

The main financial risks for Castle Biosciences investors include widening net losses, a growing accumulated deficit, and a decrease in stockholders' equity, all indicating a lack of profitability and potential for future dilution.

How does Castle Biosciences' Q2 2025 performance compare to Q2 2024?

Castle Biosciences' net loss for Q2 2025 was $28.1 million, which is a significant increase compared to the $20.5 million net loss reported in Q2 2024, indicating a worsening financial performance.

What is the current state of Castle Biosciences' equity?

As of June 30, 2025, Castle Biosciences' total stockholders' equity stood at $300.5 million, a decrease from $355.7 million at the end of 2024, reflecting the impact of ongoing operational losses.

What should investors consider given Castle Biosciences' Q2 results?

Investors should consider the persistent and increasing net losses, the growing accumulated deficit, and the declining stockholders' equity, which collectively suggest a high-risk investment profile for Castle Biosciences.

Risk Factors

Sustained Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $28.1 million for Q2 2025, an increase from $20.5 million in Q2 2024. The year-to-date net loss widened to $55.2 million from $40.1 million in the prior year. This has led to a significant accumulated deficit of $650.3 million as of June 30, 2025, up from $595.1 million at the end of 2024, indicating a persistent inability to achieve profitability.
Declining Stockholders' Equity [medium — financial]: Total stockholders' equity decreased to $300.5 million as of June 30, 2025, from $355.7 million at December 31, 2024. This decline is a direct consequence of the ongoing net losses, which erode the company's book value and could raise concerns about financial stability if losses continue unabated.
Dependence on Diagnostic Test Adoption [medium — operational]: Castle Biosciences' financial performance is heavily reliant on the market adoption and reimbursement of its diagnostic tests. Any slowdown in adoption, changes in reimbursement policies, or increased competition could materially impact revenue and profitability.
Reimbursement and Payer Landscape [medium — regulatory]: The company's ability to generate revenue is subject to obtaining and maintaining favorable reimbursement from government and private payers. Changes in healthcare policies or payer decisions could adversely affect the company's revenue streams and profitability.

Industry Context

Castle Biosciences operates in the medical laboratories sector, focusing on diagnostic tests for skin conditions. The industry is characterized by rapid technological advancements, increasing demand for personalized medicine, and evolving reimbursement landscapes. Competition comes from established diagnostic companies and emerging players offering novel testing solutions.

Regulatory Implications

The company's diagnostic tests are subject to regulatory oversight, including potential FDA review and compliance with CLIA regulations. Changes in healthcare policy, particularly regarding diagnostic test coverage and reimbursement by Medicare and private insurers, pose significant risks to revenue generation.

What Investors Should Do

[object Object]
[object Object]
[object Object]
[object Object]

Key Dates

2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing increased net losses and a widening accumulated deficit.
2025-08-04: Filing Date of 10-Q — Indicates the official release of the company's financial performance for the period ending June 30, 2025.

Glossary

Accumulated Deficit: The cumulative net losses of a company that have not been offset by net income or other gains. It represents a negative retained earnings balance. (Highlights the company's historical unprofitability, which has grown to $650.3 million as of June 30, 2025.)
Additional Paid-In Capital: The amount of capital a company has received from investors in exchange for stock, above the stock's par value. It often includes amounts from stock-based compensation. (Shows significant capital infusion, particularly from stock-based compensation, reaching $600.5 million, which supports operations despite losses.)
Stockholders' Equity: The residual interest in the assets of an entity after deducting all its liabilities. It represents the net worth of the company. (The decrease to $300.5 million reflects the impact of net losses on the company's book value.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Castle Biosciences Inc. has experienced a widening net loss in both the second quarter ($28.1M vs. $20.5M) and year-to-date ($55.2M vs. $40.1M). This trend has also led to a decrease in total stockholders' equity from $355.7M at year-end 2024 to $300.5M as of June 30, 2025, reflecting the ongoing challenges in achieving profitability. No new significant risks were explicitly detailed in the provided snippet, but the existing financial pressures are amplified.

From the Filing

0001447362-25-000097.txt : 20250804 0001447362-25-000097.hdr.sgml : 20250804 20250804161000 ACCESSION NUMBER: 0001447362-25-000097 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250804 DATE AS OF CHANGE: 20250804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC CENTRAL INDEX KEY: 0001447362 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770701774 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38984 FILM NUMBER: 251180340 BUSINESS ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 BUSINESS PHONE: 866-788-9007 MAIL ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 10-Q 1 cstl-20250630.htm 10-Q cstl-20250630 0001447362 12/31 2025 Q2 false P5Y 1 1 1 1 1 281 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure cstl:segment cstl:reporting_unit utr:sqft cstl:payment cstl:renewal_option cstl:option 0001447362 2025-01-01 2025-06-30 0001447362 2025-07-28 0001447362 2025-06-30 0001447362 2024-12-31 0001447362 2025-04-01 2025-06-30 0001447362 2024-04-01 2024-06-30 0001447362 2024-01-01 2024-06-30 0001447362 us-gaap:CommonStockMember 2023-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001447362 us-gaap:RetainedEarningsMember 2023-12-31 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001447362 2023-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001447362 2024-01-01 2024-03-31 0001447362 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001447362 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001447362 us-gaap:CommonStockMember 2024-03-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001447362 us-gaap:RetainedEarningsMember 2024-03-31 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001447362 2024-03-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001447362 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001447362 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001447362 us-gaap:CommonStockMember 2024-06-30 0001447362 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001447362 us-gaap:RetainedEarningsMember 2024-06-30 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001447362 2024-06-30 0001447362 us-gaap:CommonStockMember 2024-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001447362 us-gaap:RetainedEarningsMember 2024-12-31 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001447362 2025-01-01 2025-03-31 0001447362 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001447362 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001447362 us-gaap:CommonStockMember 2025-03-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001447362 us-gaap:RetainedEarningsMember 2025-03-31 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001447362 2025-03-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001447362 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001447362 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001447362 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001447362 us-gaap:CommonStockMember 2025-06-30 0001447362 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001447362 us-gaap:RetainedEarningsMember 2025-06-30 0001447362 us-gaap:AccumulatedOtherComprehensiveInco